Control of Immunity by the TNFR-related molecule OX40 (CD134)

Annual Review of Immunology

Volumn 28, Issue , 2010, Pages 57-78

  Croft, Michael ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

Autoimmunity; Costimulation; Infectious disease; OX40L; T cells; Vaccination

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; CD134 ANTIBODY; CD134 ANTIGEN; CYTOKINE; DNA VACCINE; OX40 LIGAND; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADJUVANT ARTHRITIS; ALLERGIC ENCEPHALITIS; ALLOGRAFT; ANTIGEN FUNCTION; ANTIGEN PRESENTING CELL; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL TYPE; CELLULAR IMMUNITY; CRYPTOCOCCUS NEOFORMANS; DIABETES MELLITUS; ENDOTHELIUM CELL; ENTERITIS; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATORY DISEASE; INFLUENZA VIRUS; LEISHMANIA MAJOR; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOID ORGAN; MAST CELL; MODULATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOCARDITIS; NATURAL KILLER T CELL; NIPPOSTRONGYLUS BRASILIENSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; VACCINIA VIRUS; ANIMAL; CELL COMMUNICATION; IMMUNOLOGY; METABOLISM; NATURAL KILLER CELL; T LYMPHOCYTE;

ANIMALS; CELL COMMUNICATION; HUMANS; KILLER CELLS, NATURAL; OX40 LIGAND; RECEPTORS, OX40; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 77952311199     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-030409-101243     Document Type: Review

References (135)

1. Paterson DJ, Jefferies WA, Green JR, Brandon MR, Corthesy P, et al. 1987. Antigens of activated rat T lymphocytes including a molecule of 50000 Mr detected only on CD4 positive T blasts. Mol. Immunol. 24:1281-1290
2. Mallett S, Fossum S, Barclay AN. 1990. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes\a molecule related to nerve growth factor receptor. EMBO J. 9:1063-1068
3. Calderhead DM, Buhlmann JE, van den Eertwegh, Claassen E, Noelle RJ, Fell HP. 1993. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J. Immunol. 151:5261-5271
4. Latza U, Durkop H, Schnittger S, Ringeling J, Eitelbach F, et al. 1994. The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur. J. Immunol. 24:677-683
5. Tanaka Y, Inoi T, Tozawa H, Yamamoto N, Hinuma Y. 1985. A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). Int. J. Cancer 36:549-555
6. Miura S, Ohtani K, Numata N, Niki M, Ohbo K, et al. 1991. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax. Mol. Cell. Biol. 11:1313-1325
7. Baum PR, Gayle RB, Ramsdell F, Srinivasan S, Sorensen RA, et al. 1994. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 13:3992-4001
8. Shimojima M, Miyazawa T, IkedaY, McMonagle EL, Haining H, et al. 2004. UseofCD134asaprimary receptor by the feline immunodeficiency virus. Science 303:1192-1195
9. Compaan DM, Hymowitz SG. 2006. The crystal structure of the costimulatory OX40-OX40L complex. Structure 14:1321-1330
10. + T cell responses. J. Immunol. 161:6510-6517
11. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. 2000. The OX40 costimula-tory receptor determines the development of CD4 memory by regulating primary clonal expansion. J. Immunol. 165:3043-3050
12. Bansal-Pakala P, Halteman BS, Cheng MH, Croft M. 2004. Costimulation of CD8 T cell responses by OX40. J. Immunol. 172:4821-4825
13. Salek-Ardakani S, Moutaftsi M, Crotty S, Sette A, Croft M. 2008. OX40 drives protective vaccinia virus-specific CD8 T cells. J. Immunol. 181:7969-7976
14. Stuber E, Neurath M, Calderhead D, Fell HP, Strober W. 1995. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 2:507-521
15. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, et al. 2000. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J. Exp. Med. 191:365-374
16. Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G. 1997. Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 159:3838-3848
17. Tanaka H, Demeure CE, Rubio M, Delespesse G, Sarfati M. 2000. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. J. Exp. Med. 192:405-412
18. Sato T, Ishii N, Murata K, Kikuchi K, Nakagawa S, et al. 2002. Consequences of OX40-OX40 ligand in-teractionsin Langerhans cell function: enhanced contact hypersensitivity responsesinOX40L-transgenic mice. Eur. J. Immunol. 32:3326-3335
19. Ito T, Amakawa R, Inaba M, Hori T, Ota M, et al. 2004. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J. Immunol. 172:4253-4259
20. Liu C, Lou Y, Lizee G, Qin H, Liu S, et al. 2008. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J. Clin. Investig. 118:1165-1175
21. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. 1999. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162:1818-1826
22. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, et al. 2005. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202:1213-1223
23. Maxwell JR, Yadav R, Rossi RJ, Ruby CE, Weinberg AD, et al. 2006. IL-18 bridges innate and adaptive immunity through IFN-γ and the CD134 pathway. J. Immunol. 177:234-245
24. + T cells via OX40-OX40 ligand interactions. J. Immunol. 173:3716-3724
25. Kashiwakura J, Yokoi H, Saito H, Okayama Y. 2004. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J. Immunol. 173:5247-5257
26. Nakae S, Suto H, Iikura M, Kakurai M, Sedgwick JD, et al. 2006. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J. Immunol. 176:2238-2248
27. Imura A, Hori T, Imada K, Ishikawa T, Tanaka Y, et al. 1996. The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells. J. Exp. Med. 183:2185-2195
28. Burgess JK, Carlin S, Pack RA, Arndt GM, Au WW, et al. 2004. Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: a possible role in asthma? J. Allergy Clin. Immunol. 113:683-689
29. Takasawa N, Ishii N, Higashimura N, Murata K, Tanaka Y, et al. 2001. Expression of gp34 (OX40 ligand) and OX40 on human T cell clones. Jpn. J. Cancer Res. 92:377-382
30. + T cell longevity. J. Immunol. 176:5975-5987
31. -accessory cells costimulate primed CD4Tcells through OX40 and CD30atsites whereTcells collaborate with B cells. Immunity 18:643-654
32. - inducer cells: evidence that IL-7 signals regulate CD30 ligand but not OX40 ligand expression. J. Immunol. 174:6686-6691
33. Salek-Ardakani S, Song A, Humphreys IR, Croft M. 2006. OX40:OX40L axis: emerging targets for immunotherapy of human disease. Curr. Immunol. Rev. 2:37-53
34. Giacomelli R, Passacantando A, Perricone R, Parzanese I, Rascente M, et al. 2001. T lymphocytes in the synovial fluid of patients with active rheumatoid arthritis display CD134-OX40 surface antigen. Clin. Exp. Rheumatol. 19:317-320
35. + T regulatory cell inhibition. J. Immunol. 176:2486-2495
36. Endl J, Rosinger S, Schwarz B, Friedrich SO, Rothe G, et al. 2006. Coexpression of CD25 and OX40 (CD134) receptors delineates autoreactive T-cells in type 1 diabetes. Diabetes 55:50-60
37. + T cells with homology to tumor necrosis factor. J. Exp. Med. 180:757-762
38. Weinberg AD, Wallin JJ, Jones RE, Sullivan TJ, Bourdette DN, et al. 1994. Target organ-specific up-regulation of the MRC OX-40 marker and selective production of Th1 lymphokine mRNA by encephalitogenic T helper cells isolated from the spinal cord of rats with experimental autoimmune encephalomyelitis. J. Immunol. 152:4712-4721
39. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, et al. 1996. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat. Med. 2:183-189
40. + T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J. Exp. Med. 188:297-304
41. Akiba H, Oshima H, Takeda K, Atsuta M, Nakano H, et al. 1999. CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells. J. Immunol. 162:7058-7066
42. Pippig SD, Pena-Rossi C, Long J, Godfrey WR, Fowell DJ, et al. 1999. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40). J. Immunol. 163:6520-6529
43. Chen AI, McAdam AJ, Buhlmann JE, Scott S, Lupher ML Jr, et al. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity 11:689-698
44. Kopf M, Ruedl C, Schmitz N, Gallimore A, Lefrang K, et al. 1999. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11:699-708
45. Higgins LM, McDonald SA, Whittle N, Crockett N, Shields JG, MacDonald TT. 1999. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease withan OX40-IgG fusion protein, but not with anOX40 ligand-IgG fusion protein. J. Immunol. 162:486-493
46. Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, et al. 2000. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J. Exp. Med. 191:375-380
47. Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. 2000. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation. Blood 95:2434-2439
48. Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, et al. 2000. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur. J. Immunol. 30:2815-2823
49. Maxwell J, Weinberg AD, Prell RA, Vella AT. 2000. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 164:107-112
50. Bansal-Pakala P, Gebre-Hiwot Jember A, Croft M. 2001. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. 7:907-912
51. + T cells in B follicles. Eur. J. Immunol. 29:1610-1616
52. Murata K, Nose M, Ndhlovu LC, Sato T, Sugamura K, Ishii N. 2002. Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J. Immunol. 169:4628-4636
53. + T cells. Immunity 15:445-455
54. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M. 2004. The costimulation-regulated duration of PKB activation controls T cell longevity. Nat. Immunol. 5:150-158
55. Salek-Ardakani S, Song J, Halteman BS, Jember AG, Akiba H, et al. 2003. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 198:315-324
56. + T cells. J. Immunol. 179:5014-5023
57. Kunitomi A, Hori T, Imura A, Uchiyama T. 2000. Vascular endothelial cells provide T cells with costimulatory signals via the OX40/gp34 system. J. Leukoc. Biol. 68:111-118
58. Ukyo N, Hori T, Yanagita S, Ishikawa T, Uchiyama T. 2003. Costimulation through OX40 is crucial for induction of an alloreactive human T-cell response. Immunology 109:226-231
59. Kober J, Leitner J, Klauser C, Woitek R, Majdic O, et al. 2008. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur. J. Immunol. 38:2678-2688
60. Weinberg AD, Thalhofer C, Morris N, Walker JM, Seiss D, et al. 2006. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J. Immunother. 29:575-585
61. Seshasayee D, Lee WP, Zhou M, Shu J, Suto E, et al. 2007. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J. Clin. Investig. 117:3868-3878
62. Kawamata S, Hori T, Imura A, Takaori-Kondo A, Uchiyama T. 1998. ActivationofOX40 signal transduc-tion pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2-and TRAF5-mediated NF-κB activation. J. Biol. Chem. 273:5808-5814
63. Arch RH, Thompson CB. 1998. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Mol. Cell. Biol. 18:558-565
64. Ye H, Park YC, Kreishman M, Kieff E, Wu H. 1999. The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol. Cell 4:321-330 (Pubitemid 29499785)
65. Song J, So T, Croft M. 2008. Activation of NF-κB1 by OX40 contributes to antigen-driven T cell expansion and survival. J. Immunol. 180:7240-7248
66. Song J, So T, Cheng M, Tang X, Croft M. 2005. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 22:621-631
67. Song J, Salek-Ardakani S, So T, Croft M. 2007. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat. Immunol. 8:64-73
68. Linton PJ, Bautista B, Biederman E, Bradley ES, Harbertson J, et al. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197:875-883
69. So T, Song J, Sugie K, Altman A, Croft M. 2006. Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment. Proc. Natl. Acad. Sci. USA 103:3740-3745
70. Prell RA, Evans DE, Thalhofer C, Shi T, Funatake C, Weinberg AD. 2003. OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. J. Immunol. 171:5997-6005
71. Lathrop SK, Huddleston CA, Dullforce PA, Montfort MJ, Weinberg AD, Parker DC. 2004. A signal through OX40 (CD134) allows anergic, autoreactive Tcells to acquire effector cell functions. J. Immunol. 172:6735-6743
72. Williams CA, Murray SE, Weinberg AD, Parker DC. 2007. OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rβ2, or T-bet. J. Immunol. 178:7694-7702
73. + T cell survival. J. Immunol. 180:2140-2148
74. + T cells. J. Immunol. 179:1427-1430
75. + Tregs. Blood 110:2501-2510
76. + Tregs. Transplantation 85:1659-1662
77. Ito T, Wang YH, Duramad O, Hanabuchi S, Perng OA, et al. 2006. OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl. Acad. Sci. USA 103:13138-13143
78. + T regulatory cells. J. Immunol. 181:8650-8659
79. + T cells into high IL-4-producing effectors. Blood 92:3338-3345
80. Rogers PR, Croft M. 2000. CD28, OX40, LFA-1, and CD4 modulation of Th1/Th2 differentiation is directly dependent on the dose of antigen. J. Immunol. 164:2955-2963
81. De Smedt T, Smith J, Baum P, Fanslow W, Butz E, Maliszewski C. 2002. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 168:661-670
82. Li J, Li L, Shang X, Benson J, Merle Elloso M, et al. 2008. Negative regulation of IL-17 production by OX40/OX40L interaction. Cell. Immunol. 253:31-37
83. Ndhlovu LC, Ishii N, Murata K, Sato T, Sugamura K. 2001. Critical involvement of OX40 ligand signals in the T cell priming events during experimental autoimmune encephalomyelitis. J. Immunol. 167:2991-2999
84. Horai R, Nakajima A, Habiro K, Kotani M, Nakae S, et al. 2004. TNF-α is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J. Clin. Investig. 114:1603-1611
85. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. 2003. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc. Natl. Acad. Sci. USA 100:5986-5990
86. Diana J, Griseri T, Lagaye S, Beaudoin L, Autrusseau E, et al. 2009. NKT cell-plasmacytoid dendritic cell cooperation via OX40 controls viral infection in a tissue-specific manner. Immunity 30:289-299
87. Matsumura Y, Hori T, Kawamata S, Imura A, Uchiyama T. 1999. Intracellular signaling of gp34, the OX40 ligand: induction of c-jun and c-fos mRNA expression through gp34 upon binding of its receptor, OX40. J. Immunol. 163:3007-3011
88. Song A, Tang X, Harms KM, Croft M. 2005. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J. Immunol. 175:3534-3541
89. Lee SW, ParkY, Song A, Cheroutre H, Kwon BS, Croft M. 2006. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J. Immunol. 177:4464-4472
90. + T cells. Immunol. Lett. 106:27-33
91. + T cell tolerance to an endogenous tumor antigen. J. Immunol. 176:974-983
92. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. 2007. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J. Immunol. 179:7244-7253
93. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. 2008. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68:5206-5215
94. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. 2000. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60:5514-5521
95. Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, et al. 2004. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J. Immunol. 173:3002-3012
96. + T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 112:559-566
97. Humphreys IR, Loewendorf A, de Trez C, Schneider K, Benedict CA, et al. 2007. OX40 costimu-lation promotes persistence of cytomegalovirus-specific CD8 T cells: a CD4-dependent mechanism. J. Immunol. 179:2195-2202
98. Song A, Song J, Tang X, Croft M. 2007. Cooperation between CD4 and CD8 T cells for antitumor activity is enhanced by OX40 signals. Eur. J. Immunol. 37:1224-1232
99. + memory T cells and their capacity for secondary expansion. J. Immunol. 175:1665-1676
100. Humphreys IR, Walzl G, Edwards L, Rae A, Hill S, Hussell T. 2003. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J. Exp. Med. 198:1237-1242
101. + T cells. J. Immunol. 181:5990-6001
102. Serghides L, Bukczynski J, Wen T, Wang C, Routy JP, et al. 2005. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7. 1 and 4-1BBL. J. Immunol. 175:6368-6377
103. + T cell memory. J. Immunol. 174:3891-3896
104. Mestas J, Crampton SP, Hori T, Hughes CC. 2005. Endothelial cell costimulation through OX40 augments and prolongs T cell cytokine synthesis by stabilization of cytokine mRNA. Int. Immunol. 17:737-747
105. Kotani A, Hori T, Matsumura Y, Uchiyama T. 2002. Signaling of gp34 (OX40 ligand) induces vascular endothelial cells to produce a CC chemokine RANTES/CCL5. Immunol. Lett. 84:1-7
106. Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, Mandelboim O. 2004. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J. Immunol. 173:6547-6563
107. Marschner A, Rothenfusser S, Hornung V, Prell D, Krug A, et al. 2005. CpG ODN enhance antigen-specific NKT cell activation via plasmacytoid dendritic cells. Eur. J. Immunol. 35:2347-2357
108. + Th cell antitumor immunity in mice. J. Clin. Investig. 117:3330-3338
109. Baumann R, Yousefi S, Simon D, Russmann S, Mueller C, Simon HU. 2004. Functional expression of CD134 by neutrophils. Eur. J. Immunol. 34:2268-2275
110. Ekkens MJ, Liu Z, Liu Q, Whitmire J, Xiao S, et al. 2003. The role of OX40 ligand interactions in the development of the Th2 response to the gastrointestinal nematode parasite Heligmosomoides polygyrus. J. Immunol. 170:384-393
111. Ierna MX, Scales HE, Schwarz H, Bunce C, McIlgorm A, et al. 2006. OX40 interactions in gastrointestinal nematode infection. Immunology 117:108-116
112. Balic A, Harcus Y, Holland MJ, Maizels RM. 2004. Selective maturation of dendritic cells by Nip-postrongylus brasiliensis-secreted proteins drives Th2 immune responses. Eur. J. Immunol. 34:3047-3059
113. Humphreys IR, Edwards L, Walzl G, Rae AJ, Dougan G, et al. 2003. OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J. Immunol. 170:6125-6132
114. Zubairi S, Sanos SL, HillS, Kaye PM. 2004. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur. J. Immunol. 34:1433-1440
115. Du X, Zheng G, Jin H, Kang Y, Wang J, et al. 2007. The adjuvant effects of costimulatory molecules on cellular and memory responses to HBsAg DNA vaccination. J. Gene Med. 9:136-146
116. Humphreys IR, de Trez C, Kinkade A, Benedict CA, Croft M, Ware CF. 2007. Cytomegalovirus exploits IL-10-mediated immune regulation in the salivary glands. J. Exp. Med. 204:1217-1225
117. Vetto JT, Lum S, Morris A, Sicotte M, Davis J, et al. 1997. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am. J. Surg. 174:258-265
118. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, et al. 2000. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164:2160-2169
119. Croft M. 2009. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9:271-285
120. Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, et al. 2008. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem. Biol. 15:675-682
121. Morris NP, Peters C, Montler R, Hu HM, Curti BD, et al. 2007. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol. Immunol. 44:3112-3121
122. Muller N, Wyzgol A, Munkel S, Pfizenmaier K, Wajant H. 2008. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J. 275:2296-2304
123. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105:2845-2851
124. Kroemer A, Xiao X, Vu MD, Gao W, Minamimura K, et al. 2007. OX40 controls functionally different T cell subsets and their resistance to depletion therapy. J. Immunol. 179:5584-5591
125. Piconese S, Valzasina B, Colombo MP. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205:825-839
126. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, et al. 2004. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J. Immunol. 172:3580-3589
127. Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, et al. 2008. Umbilical cord blood regulatory T-cell (Treg) expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112:2847-2857
128. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, et al. 2009. OX40engage-ment and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 206:1103-1116
129. Wang X, Ria M, Kelmenson PM, Eriksson P, Higgins DC, et al. 2005. Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat. Genet. 37:365-372
130. Cunninghame Graham DS, Graham RR, MankuH, Wong AK, Whittaker JC, et al. 2008. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat. Genet. 40:83-89
131. Obermeier F, Schwarz H, Dunger N, Strauch UG, Grunwald N, et al. 2003. OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in mice. Eur. J. Immunol. 33:3265-3274
132. Totsuka T, Kanai T, Uraushihara K, Iiyama R, Yamazaki M, et al. 2003. Therapeutic effect of anti-OX40L and anti-TNF-a MAbs in a murine model of chronic colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284:G595-603
133. Pakala SV, Bansal-Pakala P, Halteman BS, Croft M. 2004. Prevention of diabetes in NOD mice at a late stage by targeting OX40/OX40 ligand interactions. Eur. J. Immunol. 34:3039-3046
134. + T cellsinadjuvant arthritis. Arthritis. Res. Ther. 7:R604-15
135. Liu DM, Yan JC, Wang CP, Chen GH, Ding S, et al. 2008. The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin. Chim. Acta 397:22-26